PharmaResources (Shanghai) Co. Ltd. A Asset Resilience Ratio

Latest as of March 2026: 16.35%

PharmaResources (Shanghai) Co. Ltd. A asset resilience ratio. PharmaResources (Shanghai) Co. Ltd. A (301230) has an Asset Resilience Ratio of 16.35% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of PharmaResources (Shanghai) Co. Ltd. A to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥215.15 Million
≈ $31.48 Million USD Cash + Short-term Investments

Total Assets

CN¥1.32 Billion
≈ $192.55 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of PharmaResources (Shanghai) Co. Ltd. A (2021–2025)

Asset resilience ratio of PharmaResources (Shanghai) Co. Ltd. A from 2021 to 2025. This chart shows how PharmaResources (Shanghai) Co. Ltd. A's Asset Resilience Ratio has changed over time. Read PharmaResources (Shanghai) Co. Ltd. A (301230) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down PharmaResources (Shanghai) Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PharmaResources (Shanghai) Co. Ltd. A balance sheet assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥215.15 Million 16.35%
Total Liquid Assets CN¥215.15 Million 16.35%

Asset Resilience Insights

  • Good Liquidity Position: PharmaResources (Shanghai) Co. Ltd. A maintains a healthy 16.35% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

PharmaResources (Shanghai) Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare PharmaResources (Shanghai) Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Bavarian Nordic
CO:BAVA
Biotechnology 10.83%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

PharmaResources (Shanghai) Co. Ltd. A Asset Resilience Ratio by Year (2021–2025)

PharmaResources (Shanghai) Co. Ltd. A asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for PharmaResources (Shanghai) Co. Ltd. A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 18.95% CN¥248.98 Million
≈ $36.43 Million
CN¥1.31 Billion
≈ $192.29 Million
-0.18pp
2024-12-31 19.13% CN¥251.77 Million
≈ $36.84 Million
CN¥1.32 Billion
≈ $192.63 Million
-3.79pp
2023-12-31 22.92% CN¥340.79 Million
≈ $49.87 Million
CN¥1.49 Billion
≈ $217.62 Million
+22.10pp
2022-12-31 0.82% CN¥10.65 Million
≈ $1.56 Million
CN¥1.30 Billion
≈ $190.42 Million
+0.75pp
2021-12-31 0.07% CN¥397.68K
≈ $58.19K
CN¥557.81 Million
≈ $81.62 Million
--
pp = percentage points

About PharmaResources (Shanghai) Co. Ltd. A

SHE:301230 China Biotechnology
Market Cap
$811.00 Million
CN¥5.54 Billion CNY
Market Cap Rank
#9545 Global
#2376 in China
Share Price
CN¥30.63
Change (1 day)
+7.51%
52-Week Range
CN¥22.55 - CN¥65.76
All Time High
CN¥65.76
About

PharmaResources (Shanghai) Co., Ltd., together with its subsidiaries, operates as a one-stop integrated service provider for new drug research, development, and commercial manufacturing to pharmaceutical and biotechnology companies in China and internationally. The company offers contract research organization (CRO), contract manufacturing organization (CMO), contract development and manufacturin… Read more